COVID-19 in patients with aggressive MS treated with aHSCT: A multi-center study

ABSTRACT

Introduction: Onco-hematological patients, specifically those treated with hematopoietic stem cell transplantation (HSCT) [2], are particularly at risk of severe acute respiratory syndrome due to Coronavirus-2 (SARS-CoV-2). Conversely, evidences regarding Coronavirus Disease 2019 (COVID-19) in aggressive multiple sclerosis (MS) treated with autologous HSCT (aHSCT) are not available. At pandemic start, and in the absence of data, European Society for Blood and Marrow transplantation/Autoimmune Disease Working Party (EBMT/ADWP) suggested delaying not life-sparing HSCT. Aim: To describe cases of COVID-19 in a population of aggressive MS treated with aHSCT. Materials and Methods: Data were collected from 4 centers (march-2020 to april-2021). Patients' health-status was periodically monitored by phonecall. Patients transplanted within a 12-month period were asked to maintain a strict home-isolation. Those transplanted from longer than 12 months were asked to keep safe behaviour, as recommended by EBMT/ADWP. Results: We recorded 5 cases out of 70 patients. At COVID-19 time, mean (standard deviation) disease duration (dd) was 12.0 (±4.9) years and median expanded disability status scale (EDSS) was 4.5 (range 3.0-7.5). Mean time from aHSCT was 24.7 (±9.8) months (range 12.9-37.0). All patients presented normal lymphocyte values besides one with grade-two lymphopenia (617.0 cc/ mm